OncoMatch/Clinical Trials/NCT07150806
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Is NCT07150806 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Actinium Ac 225 DOTATATE RYZ101 and L-lysine/L-arginine-containing Amino Acid for recurrent meningioma.
Treatment: Actinium Ac 225 DOTATATE RYZ101 · L-lysine/L-arginine-containing Amino Acid — This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery
progressed after first line treatment
Cannot have received: radiopharmaceutical therapy
Prior radiopharmaceutical therapies (RPT), including radioembolization
Cannot have received: solid organ or bone marrow transplantation
Prior solid organ or bone marrow transplantation
Lab requirements
Blood counts
Hemoglobin concentration ≥ 5.0 mmol/L (≥ 8.0 g/dL); ANC ≥ 1000 cells/µL; Platelets > 100 × 10^9/L
Kidney function
Creatinine clearance (CrCl) ≥ 60 mL/min calculated using CKD-EPI equation
Liver function
AST and ALT ≤ 2.5 × ULN (or ≤ 5 × ULN if presence of liver metastases); Total bilirubin ≤ 3 × ULN; Serum albumin ≥ 3.0 g/dL
Cardiac function
NYHA Class < II heart failure; LVEF ≥ 50%; No history of MI, ACS, or coronary intervention within 6 months; QTcF ≤ 470 ms; No resistant hypertension
Sufficient renal function, as evidenced by creatinine clearance (CrCl) ≥ 60 mL/min... Hemoglobin concentration ≥ 5.0 mmol/L (≥ 8.0 g/dL)... ANC ≥ 1000 cells/µL... Platelets > 100 × 10^9/L... AST and ALT ≤ 2.5 × ULN (or ≤ 5 × ULN if presence of liver metastases)... Total bilirubin ≤ 3 × ULN... Serum albumin ≥ 3.0 g/dL... Adequate coagulation function, defined by INR/PT and aPTT ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify